Menu

In the News

July 11, 2024 • In the News

AP News: Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project

Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for early detection of Alzheimer’s dementia. BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through […]

July 11, 2024 • In the News

PharmiWeb: Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

Alzheimer's Alzheimers Bio-Hermes GAP Innovation Research
July 10, 2024 • In the News

UK Research and Innovation: UK and US join forces to tackle dementia with innovative biomarkers

10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]

Alzheimer's Alzheimers Bio-Hermes-002 GAP Innovation Research
July 10, 2024 • Press Releases

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

Collaboration with Innovate UK Yields New Partners for Alzheimer’s Study Washington D.C., July 10, 2024- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting organizations committed to improving dementia research using blood-based and digital biomarkers.   This competition received 14 proposals within one week, from […]

July 9, 2024 • In the News

Gwinnett Daily Post: Global Alzheimer’s Platform Foundation Appoints Snellville Resident Director of Recruitment And Strategic Initiatives

The Washington, D.C.-based Global Alzheimer’s Platform Foundation announced on July 8 that Snellville resident Tamiko MaGee-Rodgers has been named director of the foundation’s Recruitment and Strategic Initiatives. The nonprofit GAP was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research and lowering the cost and duration of […]

Alzheimer's Alzheimers GAP Innovation Research
July 8, 2024 • Press Releases

Global Alzheimer’s Platform Foundation Names Chief Impact Officer and Director of Recruitment & Strategic Initiatives Among Promotions 

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Alzheimer's Alzheimers GAP Innovation Research
July 2, 2024 • Press Releases

Global Alzheimer’s Platform Foundation: Full FDA Approval of Donanemab Signifies Brighter Future

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Alzheimer's Alzheimers GAP Innovation Research
July 1, 2024 • Press Releases

Global Alzheimer’s Platform Foundation Applauds FDA Draft Guidance to Improve Diverse Participation in Clinical Trials

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]

Alzheimer's Alzheimers GAP Innovation Research
June 21, 2024 • In the News

Stroll Hyde Park Magazine: Memory Issues or Normal Signs of Aging?

Resident contributor, Dr. Susan Steen breaks down three life changes to trackto prioritize your brain health as you and your loved ones age. As people age, it’s normal to experience occasional forgetfulness, however when does ‘some’ memory loss become a bigger concern? There are three aspects of your life that you can reflect on and […]

Alzheimer's Alzheimers GAP Innovation Research
June 17, 2024 • Press Releases

Global Alzheimer’s Platform Foundation Welcomes Tandem Clinical Research Site to its Network

Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]

Alzheimer's Alzheimers GAP Innovation Research